Skip to main content

Table 2 Univariate and multivariable analyses for overall survival

From: No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer

Characteristic   Univariate analysis Multivariablea analysis
No. evt/ No. pts Median OS (95% CI) HR [95% CI] P-value HR [95% CI] P-value
Age (years) 1.04 [1.00; 1.08] 0.034   
Sex
 Male 17/37 22 (20; NR) 1 0.900   
 Female 15/38 21 (20; NR 1.05 [0.52; 2.1]    
ECOG Performance status
 0–1 32/68 21 (20; 24) NA NA   
 2 0/7 NA NA    
Number of metastatic sites
 1 11/28 22 (20; NA) 1 0.500   
 ≥ 2 21/47 22 (19; NA) 1.29 [0.62; 2.68]    
Treatment
 XELIRI 11/31 22 (20; NA) 1 0.150   
 FOLFIRI 21/44 21 (20; 24) 1.71 [0.82; 3.56]    
Body mass index category (kg/m2)
 < 25 22/45 21 (19; NA) 1 0.180   
 ≥ 25 10/30 24 (21; NA) 0.60 [0.28; 1.26]    
Model 1: SMM depletion at baseline
 No 13/35 24 (20; NA) 1 0.150 1 0.791
 Yes 19/40 21 (20; 23) 1.69 [0.83; 3.43]   1.14 [0.44; 2.98]  
Model 2: L3 skeletal muscle score    0.65 [0.45; 0.94] 0.023 0.71 [0.41; 1.22] 0.211
Model 3: L3 visceral adipose tissue score    1.03 [0.71; 1.48] 0.880 1.05 [0.67; 1.64] 0.833
Model 4: L3 subcutaneous adipose tissue score    0.68 [0.46; 1.01] 0.054 0.71 [0.44; 1.14] 0.153
Model 5: L3 total adipose tissue score    0.84 [0.57; 1.23] 0.370 0.87 [0.53; 1.38] 0.557
Model 6: Skeletal muscle density (HU)    0.98 [0.94; 1.01] 0.210 1.01 [0.95; 1.06] 0.868
  1. No. evt number events, No. pts. number patients, HR Hazard ratio, CI confidence interval, p-value, ECOG Eastern Cooperative Oncology Group, HU Hounsfield Units, NA not available, SMM Skeletal Muscle mass depletion thresholds were those defined by Martin et al. [6]
  2. aEach 6 multivariable models assessing effect of each body component parameter on overall survival were adjusted for age, sex, number of metastases, treatment, BMI
\